Telix Pharmaceuticals and Radboud University Medical Centre Conclude Clinical Collaboration Agreement
MELBOURNE, Australia and NIJMEGAN, The Netherlands, March 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has today announced a clinical collaboration with Radboud University Medical Center ("Radboudumc").
Telix is developing 89Zr-girentuximab (TLX-250) for the purpose of imaging clear cell renal cell cancer (ccRCC) with Positron Emission Tomography (PET). Radboudumc and Telix will collaborate on several clinical projects in relation to TLX-250, including leading the pre-Phase III bridging/dosimetry study for TLX-250, participating as a key adviser for the Phase III study, as well as the IMPACT-RCC study (NCT02228954) to better understand how molecular imaging can be used to measure therapeutic treatment response in metastatic kidney cancer.
Telix Co-Founder and CMO Dr. Andreas Kluge stated, "Radboudumc has been a clinical leader in the use of 89Zr-Girentuximab (TLX-250) in the clinic and their patient experience underpins much of the confidence we have in the imaging agent, particularly the change in isotope to a radiometal for superior image quality, sensitivity and patient convenience. We have worked closely with Radboudumc as part of activating our clinical activity for TLX-250 in Europe."
Professor Peter Mulders, Chairman of the Department of Urology at Radboudumc noted, "We are pleased to be working with Telix to progress this very important technology from a clinical perspective. This international collaboration lays the foundation for the completion of product development of 89Zr-Girentuximab and we are delighted to be part of bringing this technology to renal cancer patients in the Netherlands and beyond."
As part of the collaboration, Telix will fund a clinical fellowship position at the Department of Radiology and Nuclear Medicine of the Radboudumc to oversee the various activities around the collaboration. The Radboudumc Technology Center imaging facility will also be a key partner, with its cutting-edge technology and expertise for pre-clinical and clinical imaging.
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX).
For more information visit www.telixpharma.com.
About Radboud University Medical Center (Radboudumc)
The Radboud University Medical Center, is the academic hospital affiliated with the Radboud University Nijmegen, in the city of Nijmegen in the eastern-central part of The Netherlands. It is one of the largest and leading hospitals of The Netherlands, providing supra-regional tertiary care for residents of a large part The Netherlands. The medical center has 1,000 beds, employs approximately 10,000 employees, and offers educational services to about 3,000 students.
For more information visit www.radboudumc.nl.
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.
None of the products described in this release have obtained a marketing authorization from the US Food and Drug Administration.
Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: email@example.com Investor and Media Relations Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: firstname.lastname@example.org
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Skybox Security Expands Footprint in APAC with New Channel Partners and Leadership in Australia20.6.2018 00:00 | Pressemelding
SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, today announced that two Australia-based firms, NEXTGEN and Insentra have joined its Australia channel partner program. In addition, Skybox has filled a key leadership role in Australia and New Zealand, continuing the company's expansion in the Asia Pacific region (APAC), which is among the company's fastest-growing global markets. The Skybox APAC channel program enables managed security service providers (MSSPs), value-added resellers (VARs), distributors and system integrators to meet the needs of the market by deploying and offering services that leverage the Skybox(TM) Security Suite. By adding the Suite to their offerings, local partners can continue to serve as trusted cybersecurity advisors to Australian businesses. "Skybox is working with many of the world's largest, most complex networks, providing security teams with the visibility and context needed to addres
Platinum Equity to Sell Worldwide Flight Services for €1.2 Billion19.6.2018 15:00 | Pressemelding
Successful investment adds to Platinum Equity's continued momentum in Europe LOS ANGELES, June 19, 2018 (GLOBE NEWSWIRE) -- Platinum Equity today announced it has signed a definitive agreement to sell Worldwide Flight Services (WFS) to affiliates of Cerberus Capital Management, L.P. in a transaction valued at approximately €1.2 billion. The sale is expected to close during Q4 2018, subject to regulatory approval and certain closing conditions. Since Platinum Equity acquired the company in 2015, WFS has grown significantly, both organically and through a transformative add-on acquisition, and is now the world's largest air cargo handler and one of the world's leading providers of ground handling and technical services, with annual revenues of more than €1.2 billion. "Through a combination of growth and operational initiatives, WFS has evolved and expanded significantly over the past three years and today enjoys record top-line and earnings performance," said Platinum Equity Partner Loui
Quantenna's New QSR10GU-AX Plus Raises the Bar for Wi-Fi Performance and Functionality19.6.2018 14:00 | Pressemelding
SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ:QTNA), the innovator and global leader of high performance Wi-Fi solutions, today announced that the QSR10GU-AX Plus, a new enhanced solution targeting gateways and access points based on the draft IEEE 802.11ax standard, is now sampling to select customers. Building upon Quantenna's pioneering QSR10G-AX Wi-Fi platform, QSR10GU-AX Plus offers unique capabilities, including Adaptive 5 GHz, SuperTx and ESP, providing significant performance gains across a variety of home configurations. The QSR10GU-AX Plus can operate concurrently in both 8x8 MIMO in the 5 GHz band and 4x4 MIMO in the 2.4 GHz band supporting a total of 12 streams. Unique features of QSR10GU-AX Plus include: Dynamic switching between 8x8 MIMO and dual 4x4 MIMO in the 5 GHz band by applying adaptive algorithms, enabled by Quantenna's unique baseband and RF architecture design. This provides the end users with the best possible MIMO c
CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents19.6.2018 14:00 | Pressemelding
SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline. CrownBio boasts the world's largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre's innovative immuno-oncology drug discovery pipeline. "Pierre Fabre recognizes the value of CrownBio's extensive PDX collection and their expertise in implementing innovative humanization strategies," said Nathalie Corvaia, P
Glatfelter to Acquire Georgia-Pacific's European Nonwovens Business for $185 Million19.6.2018 13:44 | Pressemelding
YORK, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- June 19, 2018 - Glatfelter (NYSE:GLT), a global supplier of specialty papers and engineered materials, today announced it has signed a definitive agreement to purchase Georgia-Pacific's European nonwovens business (the "Business") for $185 million, subject to customary purchase price adjustments. The proposed transaction includes Georgia-Pacific's operations located in Steinfurt, Germany, along with sales offices located in France and Italy. The Steinfurt facility produces high-quality airlaid products for the table-top, wipes, hygiene, food pad, and other nonwoven materials markets, competing in the marketplace with nonwoven technologies and substrates, as well as other materials focused primarily on consumer based end-use applications. The Steinfurt facility is a state-of-the-art, 32,000-metric-ton-capacity manufacturing facility that employs approximately 220 people. "Glatfelter's agreement to acquire the European nonwovens business demon
Industry stakeholders partner on blockchain based margin and collateral solution19.6.2018 13:00 | Pressemelding
AMSTERDAM, the Netherlands, BRUSSELS, Belgium, LONDON and STOCKHOLM, Sweden, June 19, 2018 (GLOBE NEWSWIRE) -- ABN AMRO Clearing, EuroCCP, Euroclear and Nasdaq have completed a joint proof of concept to make the use of securities more efficient when used to cover margin calls, including after business hours, using blockchain, or distributed ledger technology (DLT). This solution addresses significant business challenges and inefficiencies related to the current provision of collateral to Central Counterparties (CCPs) and has demonstrated that a shared, resilient network can be built between collateral givers, collateral takers and intermediaries. The inefficiencies of collateral processing have been heightened as a result of recent market changes such as extended trading hours by stock exchanges and the requirement to centrally clear derivatives traded bilaterally (OTC) under the European Market Infrastructure Regulation (EMIR). Today, a CCP margin call typically needs to be covered by
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom